Validation of Clinical Assays for Risk Stratification of Children With Pediatric Liver Neoplasms
小儿肝肿瘤儿童风险分层临床测定的验证
基本信息
- 批准号:10663695
- 负责人:
- 金额:$ 33.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:5 year old6 year oldAdolescentAffectBiological AssayBiological MarkersBiologyCLIA certifiedCardiotoxicityCategoriesCertificationCessation of lifeChildChildhoodCisplatinClassificationClinicalClinical TrialsCollaborationsCombination Drug TherapyCombined Modality TherapyDataDevelopmentDiagnosisDrug resistanceEnrollmentEuropeEuropeanExcisionFundingGraft RejectionHepaticHepatoblastomaHigh Dose ChemotherapyHistologyImmunotherapyImpairmentInternationalInterventionIntervention StudiesInvestigational TherapiesLesionLiverLiver neoplasmsMalignant NeoplasmsMedicalModelingMolecularMolecular DiagnosisMolecular ProfilingMorbidity - disease rateNeoplasm MetastasisNeoplasmsNonmetastaticOperative Surgical ProceduresOutcomePatient RecruitmentsPatient-Focused OutcomesPatientsPediatric NeoplasmPediatric Oncology GroupPediatric cohortPlayPreparationPrimary carcinoma of the liver cellsPrognosisPrognostic MarkerQuality of lifeResectedResistanceRiskRisk EstimateSecond Primary CancersStratificationSurvival RateTestingTherapeutic TrialsToxic effectTreatment outcomeTreatment-related toxicityTumor SubtypeUnresectableValidationWorkaggressive therapybiomarker validationchemotherapeutic agentchemotherapycohortdosagehigh riskimprovedimproved outcomeliver cancer patientliver transplantationmolecular markermolecular modelingnephrotoxicityneurotoxicityototoxicityparticipant enrollmentpersonalized medicinepredictive markerpredictive modelingpredictive testprofiles in patientsprospectiverecruitresearch clinical testingresponserisk predictionrisk prediction modelrisk stratificationtargeted treatmenttransplantation therapytreatment optimizationtumor
项目摘要
Project Summary
Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the most frequently diagnosed liver tumors in
children, with HBs most commonly present in young children less than 5 years of age, and HCCs are more
commonly seen in adolescents. HB- and HCC-patient outcomes and treatment options vary dramatically, with
5-year overall survival rates of over 70% for HB and under 30% for HCC patients. While a combination of
chemotherapy and surgery is effective for lower-risk HBs, 3-year overall survival for high-risk HBs is 50%. High-
dose chemotherapy, which is often ineffective for high-risk HBs, is associated with significant morbidity.
Complete surgical resection is the only chance for a cure for HCC. Molecular biomarkers can help optimize
treatments for patients that will not benefit from chemotherapy or that do not require high dosage chemotherapy
and identify patients that require a combination of aggressive surgery and chemotherapy.
In previous work, we, and our collaborators, identified prognostic biomarkers that distinguish between low- and
high-risk HBs at diagnosis. We proposed and retrospectively evaluated predictive models to classify patients
based on risk—including their need for aggressive therapies. These models identify patients that do not require
aggressive therapies, patients that will benefit from aggressive therapies, and patients with tumors that are more
likely to metastasize and become resistant to chemotherapy. We developed and certified molecular assays to
profile patients and tumors for predictive biomarker used by these models. Here, we propose to prospectively
validate these biomarkers, assays, and models to produce the first validated platform for the molecular diagnosis
and therapy choice for HBs and HCC. We will benefit from a close collaboration with clinical-trial produced data
in the USA and EU, including AHEP1531 (USA), ChILTERN (EU) and iPC (a EU-USA collaboration).
项目摘要
肝母细胞瘤(HB)和肝细胞癌(HCC)是最常见的肝脏肿瘤,
儿童,HB最常见于5岁以下的幼儿,HCC更多
常见于青少年。HB和HCC患者的结局和治疗选择差异很大,
5-HB患者的年总生存率超过70%,HCC患者的年总生存率低于30%。虽然一个组合的
化疗和手术对低风险的HB有效,高风险HB的3年总生存率为50%。高-
大剂量化疗通常对高危HB无效,但与显著的发病率相关。
完全手术切除是治愈HCC的唯一机会。分子生物标志物可以帮助优化
对不能从化疗中获益或不需要高剂量化疗的患者的治疗
并确定需要积极手术和化疗相结合的患者。
在以前的工作中,我们和我们的合作者,确定了区分低和低的预后生物标志物,
诊断时的高风险HB。我们提出并回顾性评估了预测模型来对患者进行分类,
包括他们对积极治疗的需求。这些模型识别出不需要
积极的治疗,患者将受益于积极的治疗,和患者的肿瘤,
可能转移并对化疗产生抗药性。我们开发并认证了分子检测,
对患者和肿瘤进行分析,以获得这些模型使用的预测性生物标志物。在此,我们建议前瞻性地
验证这些生物标志物、测定和模型,以产生第一个经验证的分子诊断平台
以及乙肝和肝细胞癌的治疗选择。我们将受益于与临床试验产生的数据的密切合作
在美国和欧盟,包括AHEP 1531(美国),奇尔滕(欧盟)和iPC(欧盟-美国合作)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dolores Lopez-Terrada其他文献
Dolores Lopez-Terrada的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Psychosocial factors as potential moderators of the association between prenatal stress from the Fort McMurray wildfire and social emotional development in 5-6 year old children
心理社会因素作为麦克默里堡野火产前压力与 5-6 岁儿童社会情绪发展之间关系的潜在调节因素
- 批准号:
467237 - 财政年份:2021
- 资助金额:
$ 33.3万 - 项目类别:
Studentship Programs
Mechanisms of Sustained Selective Attention in 2- to 6- Year-Old Children
2至6岁儿童持续选择性注意力的机制
- 批准号:
7739271 - 财政年份:2009
- 资助金额:
$ 33.3万 - 项目类别:
Stage 1 Treatment Development with Homeless Mothers and their 2-6 Year Old Childr
无家可归的母亲及其 2-6 岁儿童的第一阶段治疗发展
- 批准号:
7627037 - 财政年份:2009
- 资助金额:
$ 33.3万 - 项目类别:
Mechanisms of Sustained Selective Attention in 2- to 6- Year-Old Children
2至6岁儿童持续选择性注意力的机制
- 批准号:
7921601 - 财政年份:2009
- 资助金额:
$ 33.3万 - 项目类别:
Stage 1 Treatment Development with Homeless Mothers and their 2-6 Year Old Childr
无家可归的母亲及其 2-6 岁儿童的第一阶段治疗发展
- 批准号:
8037547 - 财政年份:2009
- 资助金额:
$ 33.3万 - 项目类别:
Stage 1 Treatment Development with Homeless Mothers and their 2-6 Year Old Childr
无家可归的母亲及其 2-6 岁儿童的第一阶段治疗发展
- 批准号:
8035834 - 财政年份:2009
- 资助金额:
$ 33.3万 - 项目类别: